84 related articles for article (PubMed ID: 19154451)
1. Disseminated tumor cells in prostate cancer patients after radical prostatectomy and without evidence of disease predicts biochemical recurrence.
Morgan TM; Lange PH; Porter MP; Lin DW; Ellis WJ; Gallaher IS; Vessella RL
Clin Cancer Res; 2009 Jan; 15(2):677-83. PubMed ID: 19147774
[TBL] [Abstract][Full Text] [Related]
2. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse.
Hartkopf AD; Wallwiener M; Fehm TN; Hahn M; Walter CB; Gruber I; Brucker SY; Taran FA
Ann Oncol; 2015 Jun; 26(6):1155-1160. PubMed ID: 25791636
[TBL] [Abstract][Full Text] [Related]
3. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients.
Tjensvoll K; Nordgård O; Skjæveland M; Oltedal S; Janssen EAM; Gilje B
BMC Cancer; 2019 Nov; 19(1):1131. PubMed ID: 31752747
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Cytokeratin-7 and Cytokeratin-19 Expression Relationship with Gleason Score in Prostatic Adenocarcinoma.
Soltanipur M; Jalali Nadoushan M; Yarmohammadi H
Iran J Pathol; 2023; 18(3):363-369. PubMed ID: 37942200
[TBL] [Abstract][Full Text] [Related]
5. Tumor removal limits prostate cancer cell dissemination in bone and osteoblasts induce cancer cell dormancy through focal adhesion kinase.
Liu R; Su S; Xing J; Liu K; Zhao Y; Stangis M; Jacho DP; Yildirim-Ayan ED; Gatto-Weis CM; Chen B; Li X
J Exp Clin Cancer Res; 2023 Oct; 42(1):264. PubMed ID: 37821954
[TBL] [Abstract][Full Text] [Related]
6. Tumor dormancy in bone.
Mayhew V; Omokehinde T; Johnson RW
Cancer Rep (Hoboken); 2020 Feb; 3(1):e1156. PubMed ID: 32632400
[TBL] [Abstract][Full Text] [Related]
7. Impact of uPA/PAI-1 and disseminated cytokeratin-positive cells in breast cancer.
Märkl B; Kazik M; Harbeck N; Jakubowicz E; Hoffmann R; Jung T; Steinfeld D; Schenkirsch G; Schlimok G; Oruzio D
BMC Cancer; 2019 Jul; 19(1):692. PubMed ID: 31307406
[TBL] [Abstract][Full Text] [Related]
8. Circulating and disseminated tumor cells: diagnostic tools and therapeutic targets in motion.
Wang H; Stoecklein NH; Lin PP; Gires O
Oncotarget; 2017 Jan; 8(1):1884-1912. PubMed ID: 27683128
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease in breast cancer: an overview of circulating and disseminated tumour cells.
Tachtsidis A; McInnes LM; Jacobsen N; Thompson EW; Saunders CM
Clin Exp Metastasis; 2016 Aug; 33(6):521-50. PubMed ID: 27189371
[TBL] [Abstract][Full Text] [Related]
10. Association between the polymorphisms of urokinase plasminogen activation system and cancer risk: a meta-analysis.
Xu Z; Meng LL; Lin J; Ling Y; Chen SX; Lin N
Onco Targets Ther; 2015; 8():2493-502. PubMed ID: 26392776
[TBL] [Abstract][Full Text] [Related]
11. Prognostic role of circulating tumor cells and disseminated tumor cells in patients with prostate cancer: a systematic review and meta-analysis.
Ma X; Xiao Z; Li X; Wang F; Zhang J; Zhou R; Wang J; Liu L
Tumour Biol; 2014 Jun; 35(6):5551-60. PubMed ID: 24563278
[TBL] [Abstract][Full Text] [Related]
12. Identification of a new epitope in uPAR as a target for the cancer therapeutic monoclonal antibody ATN-658, a structural homolog of the uPAR binding integrin CD11b (αM).
Xu X; Cai Y; Wei Y; Donate F; Juarez J; Parry G; Chen L; Meehan EJ; Ahn RW; Ugolkov A; Dubrovskyi O; O'Halloran TV; Huang M; Mazar AP
PLoS One; 2014; 9(1):e85349. PubMed ID: 24465541
[TBL] [Abstract][Full Text] [Related]
13. Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues.
Sequeiros T; García M; Montes M; Oliván M; Rigau M; Colás E; de Torres I; Morote J; Reventós J; Doll A
Biomed Res Int; 2013; 2013():283635. PubMed ID: 24371818
[TBL] [Abstract][Full Text] [Related]
14. Bone metastasis in prostate cancer: emerging therapeutic strategies.
Sturge J; Caley MP; Waxman J
Nat Rev Clin Oncol; 2011 Jun; 8(6):357-68. PubMed ID: 21556025
[TBL] [Abstract][Full Text] [Related]
15. Collagenous and non-collagenous biochemical markers of bone metastases from prostate cancer.
Zafeirakis A
Hippokratia; 2010 Jul; 14(3):164-9. PubMed ID: 20981164
[TBL] [Abstract][Full Text] [Related]
16. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
Rabbani SA; Ateeq B; Arakelian A; Valentino ML; Shaw DE; Dauffenbach LM; Kerfoot CA; Mazar AP
Neoplasia; 2010 Oct; 12(10):778-88. PubMed ID: 20927316
[TBL] [Abstract][Full Text] [Related]
17. Urokinase-plasminogen-activator receptor expression in disseminated tumour cells in the bone marrow and peripheral blood of patients with clinically localized prostate cancer.
Thomas C; Wiesner C; Melchior SW; Schmidt F; Gillitzer R; Thüroff JW; Pfitzenmaier J
BJU Int; 2009 Jul; 104(1):29-34. PubMed ID: 19154451
[TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator system in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy.
Kumano M; Miyake H; Muramaki M; Furukawa J; Takenaka A; Fujisawa M
Urol Oncol; 2009; 27(2):180-6. PubMed ID: 18439850
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
